Chair and CEO

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Institution	Shares	Value	Change
Gateway Investment Advisers	365,000	$39M	UNCHANGED
Assenagon Asset Management	218,270	$23M	INCREASED
Handelsbanken Fonder AB	189,581	$20M	INCREASED
Swedbank AB	129,518	$14M	INCREASED
Y-Intercept (Hong Kong)	101,908	$11M	NEW

Insider	Type	Shares	Value	Date
William Lewis (Chair and CEO)	EXERCISE	4,440	$76K	2026-07-23
William Lewis (Chair and CEO)	EXERCISE	6,260	$191K	2026-07-23
William Lewis (Chair and CEO)	SELL	5,872	$625K	2026-07-23
William Lewis (Chair and CEO)	SELL	4,828	$510K	2026-07-23
William Lewis (Chair and CEO)	EXERCISE	4,440	$76K	2026-07-09

Insmed, Inc. (INSM) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades